Latest news
September 12, 2024
ITM Obtains Exclusive Worldwide License from Debiopharm for CA IX-Targeted Peptide-Based Radiopharmaceutical Programs Targeting Solid Tumors
June 1, 2023
Debiopharm Shares Oncology Program Updates at ASCO 2023 for Novel WEE1 Inhibitor, and First-In-Class CA IX Theranostic Approach
March 22, 2023
Debiopharm Announces Launch of the Phase 1/2 GaLuCi Study for its CA IX-Targeted Radiopharmaceutical Program
March 25, 2020
Debiopharm expands its radiopharmaceutical footprint with an exclusive in-licensing agreement of 3B Pharmaceutical’s targeted CAIX radiotherapy